Arbutus Biopharma Corporation (ABUS) has a consensus analyst rating of Buy, based on 10 analysts covering the stock. Of those, 8 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for ABUS is $8.50, representing a +95.4% upside from the current price of $4.35. Price targets range from a low of $8.50 to a high of $8.50.
